What are the differences among the Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors regarding their indications, dosing regimens, renal function requirements, and safety profiles?

Differences Among SGLT2 Inhibitors

All SGLT2 inhibitors share similar cardiovascular and renal benefits, but differ significantly in their eGFR thresholds for initiation, dosing flexibility, and specific safety concerns—with dapagliflozin and empagliflozin now approved for use down to eGFR ≥20 mL/min/1.73 m², while canagliflozin carries unique amputation and fracture warnings.

Key Differences by Agent

Empagliflozin

• Dosing: 10 mg or 25 mg once daily 1
• eGFR Requirements:
  • Can initiate down to eGFR ≥20 mL/min/1.73 m² for heart failure 2
  • For glycemic control alone: do not initiate below eGFR 30 mL/min/1.73 m² 2
  • Once started, continue even if eGFR falls below initiation threshold 2
• FDA Indications: Glycemic control in T2D 1
• Safety Profile: No increased amputation or fracture risk documented 1

Dapagliflozin

• Dosing: 10 mg once daily 2
• eGFR Requirements:
  • Approved for initiation down to eGFR ≥25 mL/min/1.73 m² 2
  • Can continue down to eGFR ≥20 mL/min/1.73 m² 2
  • May continue even below 20 mL/min/1.73 m² until dialysis if tolerated 2
• FDA Indications: Glycemic control, heart failure, and CKD 3
• Safety Profile: No increased amputation or fracture risk documented 1

Canagliflozin

• Dosing: 100 mg daily; may increase to 300 mg if eGFR ≥60 mL/min/1.73 m² 1
• eGFR Requirements:
  • Maximum 100 mg daily for eGFR 45-59 mL/min/1.73 m² 1
  • Can initiate down to eGFR 30 mL/min/1.73 m² 2
  • May continue 100 mg daily until dialysis if tolerated 2
• FDA Indications: Glycemic control AND reduce CV death in adults with T2D and CVD 1
• Safety Profile: UNIQUE RISKS 1:
  • Increased bone fractures
  • Increased amputation risk (particularly in patients with prior amputation, severe peripheral vascular disease, neuropathy, or diabetic foot ulcers)
  • Caution with osteoporosis history

Ertugliflozin

• eGFR Requirements: Not recommended with eGFR <45 mL/min/1.73 m² 2
• Safety Profile: Shares amputation caution with canagliflozin 1
• Limited outcome trial data compared to other agents

Shared Characteristics Across All SGLT2 Inhibitors

Common Indications

• All recommended for T2D with CKD and eGFR ≥20 mL/min/1.73 m² 4
• Prioritize agents with documented kidney or cardiovascular benefits 5
• Can be used independently of baseline HbA1c or glycemic targets in high-risk patients 1

Universal Safety Considerations 1, 2

Contraindications:

• History of serious hypersensitivity reaction
• Severe renal impairment/ESRD/dialysis (though CV/renal benefits extend down to eGFR 30 mL/min/1.73 m²)

Common Cautions:

• Volume depletion: Particularly in elderly, those on diuretics, low systolic BP, or renal impairment—consider reducing diuretic dose before initiation 5
• Genital mycotic infections: 6% vs 1% placebo; counsel on hygiene 2
• Euglycemic ketoacidosis: Withhold during prolonged fasting, surgery, or critical illness 5, 2; maintain at least low-dose insulin in insulin-requiring patients
• Hypoglycemia: Reduce insulin or sulfonylurea doses when adding SGLT2i 1

Monitoring Approach

• Reversible eGFR decline on initiation is expected and generally NOT an indication to discontinue 5, 2
• Continue therapy even if eGFR falls below initiation threshold unless not tolerated or dialysis initiated 4
• No need to increase monitoring frequency beyond standard CKD care 4

Clinical Decision Algorithm

For patients with T2D and CKD (eGFR ≥20 mL/min/1.73 m²):

1. First-line choice: Empagliflozin or dapagliflozin (strongest evidence, broadest eGFR range, no amputation/fracture concerns) 4, 3

2. Consider canagliflozin only if:

   • Patient specifically needs the 300 mg dose option (eGFR ≥60 required)
   • AND has NO history of: prior amputation, severe PVD, neuropathy, diabetic foot ulcers, or osteoporosis 1

3. Avoid ertugliflozin if eGFR <45 mL/min/1.73 m² (limited flexibility) 2

4. Key implementation points 5, 2:

   • Check volume status; reduce diuretics proactively if hypovolemia risk
   • Educate on sick day protocol (hold during illness)
   • Reduce insulin/sulfonylurea doses to prevent hypoglycemia
   • Counsel on genital hygiene
   • Do NOT discontinue for reversible eGFR dip

The glucose-lowering efficacy diminishes as eGFR declines, but cardiovascular and renal benefits persist—this is why continuation below initiation thresholds is recommended 2.